Please login to the form below

Not currently logged in
Email:
Password:

Nektar

This page shows the latest Nektar news and features for those working in and with pharma, biotech and healthcare.

BMS finds a new immunotherapy partner with $12m Compugen deal

BMS finds a new immunotherapy partner with $12m Compugen deal

In February, it signed a huge $3.6bn deal to pair Nektar's NKTR-214 with Opdivo and its CTLA4 inhibitor Yervoy (ipilimumab) in a host of tumour types.

Latest news

More from news
Approximately 7 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    article – but, as recent experience with Incyte and Nektar Therapeutics has shown, not all new drugs and combinations will succeed. ... Nektar Therapeutics’CD122 agonist NKTR-214 posted mixed results in mid-stage trials alongside Opdivo in solid

  • Deal Watch September 2016 Deal Watch September 2016

    A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe. Onzeald (etirinotecan pegol), long-acting topoisomerase I inhibitor for metastatic breast cancer (phase III). ‡‡

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics